Ocular Therapeutix Dirección
Dirección controles de criterios 1/4
El CEO de Ocular Therapeutix's es Pravin Dugel, nombrado en Apr 2024, tiene una permanencia de menos de un año. posee directamente un 0.54% de las acciones de la empresa, con un valor de $4.83M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 4.9 años, respectivamente.
Información clave
Pravin Dugel
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 1.4yrs |
| Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
Recent updates
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates
May 13CEO
Pravin Dugel (60 yo)
less than a year
Permanencia
Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Presid...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chief Financial Officer | 6.8yrs | US$1.34m | 0.050% $ 386.1k | |
| Chief Scientific Officer | less than a year | US$329.90k | 0.031% $ 236.8k | |
| Chief Medical Officer | 3.4yrs | US$1.48m | 0.019% $ 147.0k | |
| Executive Chairman | less than a year | sin datos | 0.032% $ 245.2k | |
| Chief Operations Officer | less than a year | sin datos | sin datos | |
| Chief Technology Officer | no data | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| General Counsel | 3.8yrs | US$2.41m | sin datos | |
| Vice President of Global Sales & Marketing | no data | sin datos | sin datos | |
| Vice President of Human Resources | 3.8yrs | sin datos | sin datos | |
| Chief Commercial Officer | 1.4yrs | sin datos | sin datos | |
| Chief Development Officer | less than a year | sin datos | sin datos |
1.4yrs
Permanencia media
63yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de OCUL no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | less than a year | sin datos | 0.032% $ 245.2k | |
| Lead Independent Director | 16.4yrs | US$303.61k | 0.031% $ 239.4k | |
| Independent Director | 2.8yrs | US$263.61k | 0.0058% $ 44.1k | |
| Independent Director | 11.6yrs | US$261.11k | 0.090% $ 685.2k | |
| Independent Director | less than a year | US$397.89k | sin datos | |
| Independent Director | 5.3yrs | US$261.11k | 0.0087% $ 66.3k | |
| Independent Director | 5yrs | US$248.61k | 0.0058% $ 44.1k |
5.0yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de OCUL se considera experimentada (4.8 años de antigüedad promedio).